Answers from the Lab

(00:43)
 Could you please provide us with a little background on yourself, sir?
 
 

(01:05)
 So Dr. McKeon, can you just give us a brief overview on what this test is?
 

(02:18)
 And you mentioned the CRMP-5 antibody and recoverin antibody. Are those the only two antibodies involved in this particular evaluation?

(02:43)
 So those two antibodies, are they both tested up front ? And then, if so, are there any reflexes in this evaluation?

(03:25)
 What will the results look like when a physician orders this test? Will they just get a positive or negative, or are there a titer levels that are more significant? Can you help us?

(04:24)
 This testing, like a lot of our autoimmune testing, is going to confirm that diagnosis based on the patient presentation that you described just a few minutes ago. Is that right, sir?

(05:21)
 Do you have any other advice on when physicians should be ordering this test?

(06:25)
 So what testing is currently available on the market? Maybe you can explain that, and how is ours different than what's currently available? 
 
(07:08)
 And why haven't we, sir?

(07:40)
 I know recoverin is a brand new test for us. Is that also going to be available as a stand-alone where clients can order that? And then maybe, if so, could you elaborate on when that would be appropriate to order by itself?

(08:45)
 Are there any other complementary tests that our audience should know about — maybe separate from autoimmune testing — that help to guide a diagnosis of paraneoplastic retinopathy or cancer-associated retinopathy?

(09:58)
 I think that's really clear. But just to review, is the autoimmune testing ordered before those other tests, at the same time, or after?

(10:29)
 I think a good place to end is how this testing is going to help patient care. Referring back to the struggles in this area with this patient population currently, and then how our test is going to be able to help direct a diagnosis or maybe prognosis and treatment. Can you talk about those things?

(12:53)
 Are there any additional patient presentations that have been found with recoverin?

 
(14:22)
 So if there are any questions about when to order this test or what to do with the results, they can really reach out to us anytime. Right, Dr. McKeon?
 
 

(00:55)
 Dr. Murray, as we get started today, could you tell us a little bit more about yourself and your background here?

(01:50)
 As you developed this assay, can you just give us a brief overview of it and how it works?

(04:07)
 As you compare those two methods, what are some of the things that you're seeing that are the advantages of this new test?

(07:02)
 When should patients really have this testing, and when are we performing it here at Mayo?
 
 (11:54)
 What do you think is one of the most interesting findings as you've gone through this whole process and work to develop and validate this testing? Which one really stands out to you more than anything? 

(00:50)
 Would you be able to tell us a little bit about yourself and your background?
 

(01:26)
 So would you be able to provide us a brief overview of this assay?

(02:16)
 When thinking about the application of this test, which patients should have this testing, and when should it be performed?

(03:09)
 So after the test has been performed, how are the results used to guide patient care?

 
(04:33)
 So what alternative testing options are available, and how might those compare to pancreatic elastase?

(09:32)
 When you're meeting with a patient, and perhaps their parents or guardian, how do you typically explain why you're having this test?
 
 (10:47)
 Is there anything else you'd like to share with us today about this test?

Resources

• Pancreatic Elastase, Feces (Mayo Test ID: ELASF)
• Pancreatic Disease Testing